Related references
Note: Only part of the references are listed.Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study
David Martinez-Cuadron et al.
BLOOD ADVANCES (2022)
Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain
Antonio Solana-Altabella et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2021)
Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia
Kathleen F. Villa et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database
Bhavik J. Pandya et al.
ADVANCES IN THERAPY (2019)
Acute Myeloid Leukemia, Version 3.2019
Martin S. Tallman et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain
Blanca Boluda et al.
PHARMACOECONOMICS-OPEN (2019)
Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain
Ainhoa Arenaza et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2019)
Burden of Acute Myeloid Leukemia Among Older, Newly Diagnosed Patients: Retrospective Analysis of Data From the 2010-2012 Medicare Limited Data Set
Naomi C. Sacks et al.
CLINICAL THERAPEUTICS (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations
Eytan M. Stein et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia
May Hagiwara et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse
William Irish et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit
Anna B. Halpern et al.
JAMA ONCOLOGY (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry
Erik Hulegardh et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States
Bruno C. Medeiros et al.
ANNALS OF HEMATOLOGY (2015)
Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study
Lene Sofie Granfeldt Ostgard et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients
Xiao-Qian Xu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
Jeffrey E. Lancet et al.
BLOOD (2014)
Acute myeloid leukaemia in Western Australia 1991-2005: a retrospective population-based study of 898 patients regarding epidemiology, cytogenetics, treatment and outcome
S. A. Gangatharan et al.
INTERNAL MEDICINE JOURNAL (2013)
The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands
Annemieke Leunis et al.
LEUKEMIA RESEARCH (2013)
Survival for older patients with acute myeloid leukemia: a population-based study
Betul Oran et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
Sabine Kayser et al.
BLOOD (2011)
Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment
Roland B. Walter et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Reasons for treating secondary AML as de novo AML
Lene Sofie Granfeldt Ostgard et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes
Utz Krug et al.
LANCET (2010)
Secondary acute myeloid leukemia - a single center experience
T. Szotkowski et al.
NEOPLASMA (2010)
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials
Keith Wheatley et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
Richard A. Larson
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
AML with 11q23/MLL abnormalities as defined by the WHO classification:: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases
C Schoch et al.
BLOOD (2003)
Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden
M Åström et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
